ID   DERL-7
AC   CVCL_2017
SY   DERL7; DERL-NK7
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   Cell_Model_Passport; SIDM01508
DR   Cosmic; 2785208
DR   DSMZ; ACC-524
DR   DSMZCellDive; ACC-524
DR   Wikidata; Q54830979
RX   PubMed=10800166;
RX   PubMed=11587224;
RX   PubMed=28122867;
RX   PubMed=31160637;
CC   Part of: LL-100 blood cancer cell line panel.
CC   Doubling time: 72 hours (PubMed=11587224); ~30 hours (DSMZ=ACC-524).
CC   HLA typing: A*02:01:01,26:01:01; B*38:01:01,51:01:01; C*02:02:02,12:03:01 (DSMZCellDive=ACC-524).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): DSMZ=ACC-524; PubMed=11587224
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 10,11
ST   D18S51: 14
ST   D19S433: 13,15
ST   D21S11: 29,30
ST   D2S1338: 23,24
ST   D3S1358: 14,15
ST   D5S818: 10,11
ST   D7S820: 11,12
ST   D8S1179: 13,14
ST   FGA: 20,22 (DSMZ=ACC-524)
ST   FGA: 21,22 (PubMed=11587224)
ST   Penta D: 11,13
ST   Penta E: 11,14
ST   TH01: 9
ST   TPOX: 8,11
ST   vWA: 17,19
DI   NCIt; C8459; Hepatosplenic T-cell lymphoma
DI   ORDO; Orphanet_86882; Hepatosplenic T-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_2016 ! DERL-2
SX   Male
AG   30Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 18
//
RX   PubMed=10800166;
RA   Camera A., Pezzullo L., Villa M.R., Luciano L., Pane F., Izzo B.,
RA   Boccuni P., Di Noto R., Del Vecchio L., Salvatore F., Rotoli B.;
RT   "Coexistence of two distinct cell populations (CD56(+)TcRgammadelta(+)
RT   and CD56(+)TcRgammadelta(-)) in a case of aggressive CD56(+)
RT   lymphoma/leukemia.";
RL   Haematologica 85:496-501(2000).
//
RX   PubMed=11587224; DOI=10.1038/sj.leu.2402239;
RA   Di Noto R., Pane F., Camera A., Luciano L., Barone M., Lo Pardo C.,
RA   Boccuni P., Intrieri M., Izzo B., Villa M.R., Macri M., Rotoli B.,
RA   Sacchetti L., Salvatore F., Del Vecchio L.;
RT   "Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/Tcry5+)
RT   and DERL-7 (CD56+/CD3-/TCRgammadelta-), derived from a single patient
RT   with CD56+ non-Hodgkin's lymphoma.";
RL   Leukemia 15:1641-1649(2001).
//
RX   PubMed=28122867; DOI=10.1158/2159-8290.CD-16-0330;
RA   McKinney M., Moffitt A.B., Gaulard P., Travert M., de Leval L.,
RA   Nicolae A., Raffeld M., Jaffe E.S., Pittaluga S., Xi L.-Q., Heavican T.,
RA   Iqbal J., Belhadj K., Delfau-Larue M.-H., Fataccioli V., Czader M.B.,
RA   Lossos I.S., Chapman-Fredricks J.R., Richards K.L., Fedoriw Y.,
RA   Ondrejka S.L., Hsi E.D., Low L., Weisenburger D.D., Chan W.C.,
RA   Mehta-Shah N., Horwitz S., Bernal-Mizrachi L., Flowers C.R.,
RA   Beaven A.W., Parihar M., Baseggio L., Parrens M., Moreau A.,
RA   Sujobert P., Pilichowska M., Evens A.M., Chadburn A., Au-Yeung R.K.-H.,
RA   Srivastava G., Choi W.W.L., Goodlad J.R., Aurer I., Basic-Kinda S.,
RA   Gascoyne R.D., Davis N.S., Li G.-J., Zhang J., Rajagopalan D., Reddy A.,
RA   Love C.L., Levy S., Zhuang Y., Datta J., Dunson D.B., Dave S.S.;
RT   "The genetic basis of hepatosplenic T-cell lymphoma.";
RL   Cancer Discov. 7:369-379(2017).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//